Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry

BACKGROUND: In this study, we examined patients who had non-progressive disease for at least 2 years after diagnosis of inoperable locoregional recurrent or metastatic breast cancer under continuous trastuzumab treatment. Our primary goal was to assess the long-term outcome of patients with durable...

Descripción completa

Detalles Bibliográficos
Autores principales: Witzel, Isabell, Müller, Volkmar, Abenhardt, Wolfgang, Kaufmann, Manfred, Schoenegg, Winfried, Schneeweis, Andreas, Jänicke, Fritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230522/
https://www.ncbi.nlm.nih.gov/pubmed/25371387
http://dx.doi.org/10.1186/1471-2407-14-806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230522/
https://www.ncbi.nlm.nih.gov/pubmed/25371387
http://dx.doi.org/10.1186/1471-2407-14-806

Ejemplares similares